Daily News |

The Sanofi-Aventis Multaq must be considered one of the main options for treating atrial fibrillation, one of the most frequent disorders of cardiac rhythm, recommended on Sunday the European Society of Cardiology (ESC).

This recommendation is a key support rider for a drug that has so far achieved only modest commercial start.

The Multaq (dronedarone) is intended to replace an older molecule, amiodarone, and has fewer risk factors than the latter, but it has generated to date that relatively weak sales in the U.S. and Europe because several studies have found limited effectiveness.

In its new recommendations on the management of atrial fibrillation (AF), ESC Multaq attributed to a Class 1 recommendation, which means it is a safer treatment option even though it may be less effective.

"Given the superior advantages in terms of safety and potential outcomes, the dronedarone might be preferable as a first option antiarrhythmic" explain the recommendations, published at the ESC congress in Stockholm.

The paper also highlights, for the first time the importance of reducing the duration of hospitalization of patients with atrial fibrillation, a result of Multaq found in a pivotal clinical trial.

The drug is not recommended for patients with severe heart weakness.

"Sanofi-Aventis is pleased with this recommendation Multaq first line in the FA, which constitutes a recognition of the extensive clinical development program of the drug and the innovative results achieved in terms of reduced hospitalizations from cardiovascular causes," said Marc Cluzel, executive vice president in charge of research and development in the pharmaceutical group, in a statement.

The marketing of Multaq was approved in the United States in July 2009 and last September in the European Union.He is considered one of the main growth potential of Sanofi for years to come, which will be marked by the patent expiry of several key products groups, which include cancer Taxotere or anticoagulant Plavix.

The Multaq could generate an annual turnover of 1.2 billion euros in 2014 according to consensus estimates of analysts by Thomson Reuters.

The growth of manufacturing in the euro area picked up slightly in July, thanks to the dynamism of the sector in Germany, show the final results of the monthly survey Markit.

The PMI final Markit purchasing managers stood at 56.7 against a flash estimate to 56.5 and 55.6 in June

So the tenth straight month that the index is above the 50 mark that separates growth from contraction in activity.

"It seems that the improvement is reflected in the PMI in the euro area in July is almost entirely due to an acceleration of growth in Germany," said Chris Williamson, chief economist at Markit.

The component output rose to 58.7 in July, up slightly from the initial estimate of 58.3 and 57.2 higher than the figure for the month of June

The employment rose to 51.1 against 50.4 in June, the highest since May 2008, again due to improved labor market in Germany.

Citigroup reported Friday a net profit of 2.7 billion dollars for the second quarter, down 37% year on year, due to lower revenue in the banking business.

Per diluted share, net income stood at 9 cents.

In the second quarter of 2009, net income was set at 4.28 billion dollars or 49 cents per share.

Analysts on average expected a profit of 5 cents per share excluding exceptional items for the second quarter, according to Reuters Estimates.It is not known if the EPS of 9 cents can be compared to the consensus of 5 cents.

The bank, which the U.S. government is a shareholder, said its credit losses are down for the fourth consecutive quarter.

In pre-market value fell by 2.2% to 4.07 dollars.

Boeing said Friday it has formally responded to the call for tenders for tanker aircraft, the U.S. Air Force.

The aircraft proposed by Boeing is to replace 179 KC-135 U.S. Air Force Eisenhower era.

The Boeing said to have the ability to produce at a rate of production will be required.

The European EADS has submitted his proposal on Thursday.

Sanofi-Aventis is planning acquisitions in the United States, including one or two that could cost him at least $ 15 billion, told Reuters a source familiar with the matter.

Speculation that laboratories such as Biogen, Genzyme and Allergan may be targets of the French pharmaceutical group drove up the price of these companies at the NYSE.

In the afternoon in New York, the action took 4.4% Biogen, Genzyme 5% and 6% with Allergan stock market valuations of approximately 13 billion, 13.5 billion and 18 billion dollars respectively.

The Board of Directors of Sanofi met in Paris this week and discussed several options for acquisitions, but no decision has been taken on potential targets, said the source told Reuters.

The latter, which is not authorized to speak to reporters, spoke on condition of anonymity.

In turn, a spokesman for Sanofi, the world number six from the pharmacy, simply stated that "the group's policy is to not comment on market rumors."

The Bloomberg had initially reported that Sanofi was preparing to acquire a U.S. company worth at least $ 20 billion.

GOOD STRATEGIC DECISION

Faced with competition from generic drugs, the group is actively looking for potential targets, which should enable it to find new sources of growth.

"In the big pharmaceutical companies, everyone is watching and there are whole departments that work on potential acquisitions," says Thierry Verrecchia, analyst at Raymond James.

The acquisition of a U.S. biotech is an excellent strategic decision, observed Fabian Wenner, an analyst at UBS.

"They need essentially biological expertise in antibodies," he says, adding that, therefore, Biogen and Allergan may be on the radar screen of Sanofi, while Amgen Bristol-Myers Squibb or appear to be too large pieces to swallow for French.

Sanofi announced Wednesday the acquisition of American TargeGen for some 560 million dollars (458.5 million euros), an operation designed to strengthen the group's positions in oncology.

The title Sanofi closed Friday at 47.06 euros, down 2.42%, giving a market capitalization of nearly 61.7 billion euros. The action has underperformed the DJ Stoxx sector index (-1.17%) and the CAC 40 (+0.25%). She has lost 12% since the beginning of the year.

"The share price decline as investors worried about the price. But if the acquisition was accretive, it would not be that bad," observes Fabian Wenner.

Registrations of new cars in France fell 1.2% in June on a year to $ 240,587, announced the Committee of French Automobile (CCFA).

The month of June were 22 working days, against 21 last year.A comparable number of working days, the decline in sales stood at 5.7%.

Of the first six months of 2010, registrations in France stand up 5.4% on a reported basis, to 1,212,492 units, and 3.7% in comparable number of working days from the same period of 2009.

Sales of French brands fell 7.9% in June, while those of foreign brands rose 7.8%.

Sales of passenger cars by PSA Peugeot Citroen fell 5.6% in June, while those of Renault were down 1.0%.

Registrations only Dacia (Logan, Sandero and Duster) almost doubled (95.8%), while those of Renault fell 11.1%.

Sales of the Citroën show a decline of 7.3% and Peugeot were down 4.1%.